A Multi-Centre Real-World Evaluation of Ritlecitinib in Severe Alopecia Areata: Early Real World Experience in a British Cohort
Clicks: 2
ID: 318656
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #173 of 176 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
In this UK multi-centre study of 54 patients with severe alopecia areata, oral ritlecitinib 50 mg daily achieved a 27.8% (15/54) success rate (SALT≤20) at six months, demonstrating real-world efficacy and safety profiles comparable to pivotal clinical trials. Notably, success was numerically lower in patients with skin of colour (13.3% vs. 33.3% in Caucasian patients), a subgroup that presented with significantly higher baseline disease severity and a higher likelihood of past DCP or systemic treatment.
| Reference Key |
openalex_W7165804115
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Danning Li, Radhika Bhanot, S Nayyar, V. G. Wong, Kareem Hassanin, Graciaa Singhal, Sarah Elhabrouk, D. Thompson, James Halpern, Simon Tso, Tang Ngee Shim, Kashini Andrew |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag272
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.